CAG Webinar Program
The CAG Webinar program covers a wide array of GI-focused topics with outlined learning objectives to meet the educational needs of CAG members, including Adult and Pediatric Gastroenterologists, Basic Scientists, and Trainees.
Watching recordings of the CAG Webinar program is considered a Section 2: Self-learning, Scanning activity by the Royal College of Physicians and Surgeons of Canada Maintenance of Certification program. Each recording is valued at 0.5 Section Two Credits.
The webinars are available through the MyCAG member portal. Log in to your MyCAG account to start watching. Already logged in?
Not a CAG member? Become one!
Recording coming soon:
Available webinars:
CAG/AbbVie/J&J/Pfizer/Takeda
IBD Update Post UEGW 2024
Featuring:
- Dr. John Marshall, McMaster University
- Dr. Jeff McCurdy, University of Ottawa
- Dr. Waqqas Afif, McGill University
- Dr. Sally Lawrence, BC Children's Hospital
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe key learnings from clinical trial results and new research in IBD
- Discuss emerging IBD therapies and management strategies
- Integrate these learnings into your clinical practice, to improve patient outcomes
This CAG program was co-developed with AbbVie Corporation, J&J Innovative Medicine, Pfizer Canada, Takeda Canada and was planned to achieve scientific integrity, objectivity and balance.
CAG/Takeda
IBD Update Post DDW 2024
Featuring:
- Dr. Aline Charabaty, Johns Hopkins School of Medicine
- Dr. Waqqas Afif, McGill University
- Dr. Jeff McCurdy, University of Ottawa
- Dr. Cynthia Seow, University of Calgary
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe key learnings from clinical trial results and new research in IBD
- Discuss emerging IBD therapies and management strategies
- Integrate these learnings into your clinical practice, to improve patient outcomes
This CAG program was co-developed with Takeda Canada and was planned to achieve scientific integrity, objectivity and balance.
CAG/Takeda
IBD Update from ECCO 2024
Featuring:
- Dr. Brian Feagan, Western University
- Dr. Jeff McCurdy, University of Ottawa
- Dr. Waqqas Afif, McGill University
- Dr. Reena Khanna, Western University
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe key learnings from clinical trial results and new research in IBD
- Discuss emerging IBD therapies and management strategies
- Integrate these learnings into your clinical practice, to improve patient outcomes
This CAG program was co-developed with Takeda Canada and was planned to achieve scientific integrity, objectivity and balance.
CAG/Janssen
AI in IBD and Beyond
Featuring:
- Mark Borgaonkar, MD, MSc, FRCPC, FACG, CAGF
- Alan Barkun, MD, CM, FRCPC, FACP, FACG, AGAF, MSc
- Peter Bossuyt, MD, PhD
- Vipul Jairath, MBChB, DPhil
- Kerri Novak, MD, FRCPC
- Michael F. Byrne, MD, MA, FRCPC, MRCP
Learning Objectives
Upon completion of this program, participants will be able to:
- Describe the use of AI in IBD risk stratification and prognostication
- Integrate AI into IBD scoring systems in their clinical practice
- Employ AI to help personalize their approach to patient care
CAG/Incyte
CHOLABORATE: Updated Approaches to Cholangiocarcinoma Management
Featuring:
- Avijit Chatterjee, MD
- Pushpa Sathya, MD
- Michael Carter, MD
- Hatim Karachiwala, MD
Learning Objectives
Upon completion of this program, participants will be able to:
- Explain the diagnostic process and challenges for patients with cholangiocarcinoma (CCA)
- Describe methods to detect genomic abnormalities in CCA and the tissue requirements to ensure successful genomic testing
- Apply knowledge of the evolving treatment options for patients with CCA in clinical practice
CAG/Pfizer
Settling Behaviour in IBD
Featuring:
- Mark Borgaonkar, MD, MSc, FRCPC
- Yvette Leung, MD, FRCPC
Learning Objectives
Upon completion of this program, participants will be able to:
- Identify patients with IBD who exhibit settling behaviour with their treatment
- Identify barriers and areas of discordance in both communication and treatment priorities between patients and gastroenterologists
- Apply appropriate treatment strategies and tools aimed at addressing settling behaviour in patients with inadequately controlled IBD through case discussion